GLP-1 Market Poised for 11.1% CAGR Growth Amid Increasing Demand for Weight-Loss Therapies

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds), Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type of Agonist (Single-agonist, Dual-agonist and Tri-agonist), Route of Administration (Oral and Parenteral), Target indication (Alzheimer's Disease, Non-Alcoholic Steatohepatitis, Obesity, Sleep Apnea, Type 2 Diabetes)- Market Outlook And Industry Analysis 2034"

The Global GLP-1 Market is valued at USD 50.0 Billion in 2024, and it is expected to reach USD 141.9 Billion by the year 2034, with a CAGR of 11.1% during the forecast period of 2025-2034..

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592

Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone secreted by the gastrointestinal tract that plays a critical role in maintaining glucose homeostasis and regulating appetite. GLP-1 receptor agonists are therapeutic agents engineered to activate GLP-1 receptors, producing a range of clinically beneficial effects.

These include stimulating glucose-dependent insulin secretion from pancreatic beta cells, inhibiting glucagon release, delaying gastric emptying, and enhancing peripheral glucose uptake. Consequently, GLP-1 receptor agonists have demonstrated strong efficacy in the management of type 2 diabetes while concurrently promoting weight reduction-an important therapeutic advantage for patients with obesity or metabolic disorders.

Several GLP-1 receptor agonists have also received regulatory approval for obesity management due to their appetite-suppressing and weight-loss properties. The GLP-1 receptor agonist market includes both approved and investigational therapies, encompassing short-acting agents such as exenatide and lixisenatide, as well as long-acting formulations including semaglutide, dulaglutide, and liraglutide. The introduction of oral therapies, such as oral semaglutide (Rybelsus), has further enhanced patient convenience and treatment accessibility.

Moreover, the development of next-generation GLP-1 agents-such as dual and tri-agonists like tirzepatide, which act on multiple hormonal pathways-represents a significant advancement in metabolic disease management. Market growth is primarily driven by the increasing global prevalence of type 2 diabetes and obesity, coupled with the proven clinical efficacy, safety, and versatility of existing GLP-1 therapies. Continued innovation, ongoing clinical research, and expanding therapeutic indications are expected to further strengthen the GLP-1 receptor agonist market over the coming years.

List of Prominent Players in the GLP-1 Market:
• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The growing global prevalence of type 2 diabetes and obesity serves as a key catalyst for the expansion of the GLP-1 receptor agonist market. According to data published in the Journal of the American Medical Association, diabetes prevalence rose from 3.0% to 4.1%, while obesity rates increased from 32.7% to 40.9% between 2009 and 2020. GLP-1 receptor agonists have demonstrated robust clinical efficacy in reducing blood glucose levels, lowering HbA1c concentrations, and promoting substantial weight loss.

Regulatory milestones-such as the approval of semaglutide (Wegovy) for obesity management in addition to diabetes treatment-have broadened the eligible patient base, thereby accelerating market growth. Furthermore, improvements in insurance coverage and affordability are enhancing treatment accessibility. Technological advancements in drug delivery, including oral formulations and once-weekly injectable options, are further improving patient convenience, compliance, and long-term therapeutic outcomes.

Challenges:
Despite their clinical success, several challenges impede the widespread adoption of GLP-1 receptor agonists. Common gastrointestinal side effects, including nausea and vomiting, can affect patient tolerance and adherence to therapy. Although once-weekly injectable formulations provide enhanced convenience, the requirement for subcutaneous administration continues to be a limitation for some patients.

Meanwhile, oral therapies such as semaglutide have improved accessibility, but there remains a strong demand for ultra-long-acting agents that enable less frequent dosing. Additionally, the high cost of treatment and disparities in insurance coverage, particularly across low- and middle-income countries, restrict market access and limit the broader utilization of these therapies.

Regional Trends:
The Asia-Pacific (APAC) region is emerging as one of the fastest-growing markets for GLP-1 receptor agonists, driven by rising incidences of diabetes and obesity in key countries such as China, India, and Japan. This growth is further supported by expanding healthcare infrastructure, an increasing focus on chronic disease management, and a large, underserved patient population.

The growing prevalence of metabolic disorders is generating heightened demand for effective and innovative therapeutic options. In response, leading pharmaceutical companies are expanding their regional presence and investing in the development and commercialization of advanced GLP-1 therapies to address the evolving healthcare landscape in the APAC market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2592

Recent Developments:
• In November 2023, The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
• In Dec 2021, Shanghai Innogen Pharma successfully completed a $120 million Series A funding round to support its Phase III trial of supaglutide, a GLP-1 agonist targeting diabetes. The funds will also be used to advance several first-in-class programs and establish a clinical trial manufacturing facility.

Segmentation of GLP-1 Market-
By Type of Molecule:
• Biologics
• Small Molecules
By Active Compound Used:
• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds
By Type of GLP-1 Agonist Drugs:
• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist
By Type of Agonist:
• Single agonist
• Dual agonist
• Tri-agonist
By Route of Administration:
• Oral
• Parenteral
By Target Indication:
• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/glp-1-market/2592

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.